Presenting companies at China Focus@JPM Week

China Focus@JPM Week
Jan 6th, 2019
JW Marriott San Francisco Union Square,
515 Mason St, San Francisco, CA 94102

17 companies will present at China Focus@JPM Week. Each company was reviewed and selected to present based upon their innovative science and product.

Please check our website or click here to see the presenting full list.

Register Today
Company name: Targovax
Company website: www.targovax.com
Primary therapeutic area(s): Immunotherapy
Phase of development: Ph I/II
Company name: eTheRNA immunotherapies NV
Company website: www.etherna.be
Primary therapeutic area(s): Immunotherapy
Phase of development: Clinical Development – phase I/II
Company name: Astrocyte Pharmaceuticals, Inc.
Company website: https://www.astrocytepharma.com
Primary therapeutic area(s): Acute neurology including acute ischemic stroke (AIS), traumatic brain injury (TBI) and concussion, which are leading causes of death and disability worldwide.
Phase of development: Preclinical
Company name: HPBio
Company website: www.hpbio.co.kr
Primary therapeutic area(s): Obesity, Wound/Scar treat, Allergy, Neurodegenerative disease
Phase of development: Preclinical
Company name: Elasmogen Ltd
Company website: www.elasmogen.com
Primary therapeutic area(s): Ophthalmology, oncology, inflammation, auto-immune diseases
Phase of development: Late pre-clinical
Company name: MGI/BGI
Company website: http://www.mgitech.cn/
Primary therapeutic area(s): Cancer, prenatal, all health-related diagnostics
Phase of development: Products on the market
Company name: ProMIS Neurosciences
Company website: www.promisneurosciences.com
Primary therapeutic area(s): Central nervous system diseases (CNS): Alzheimer’s disease, Parkinson’s disease, ALS
Phase of development: Preclinical development for Alzheimer’s, Parkinson’s and ALS
Company name: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
Company website: www.atombp.com/en/
Primary therapeutic area(s): kidneys disease, gout, hyperuricemia; Gastric cancer, colon cancer and breast cancer;
Phase of development: ABP-671 for gout treatment is in phase 1 clinical trials in the US/ABP-6016 for NASH treatment is under pre-clinical studies/ABP-431 for anti-cancer is under pre-clinical studies.
Company name: GLAdiator Biosciences
Company website: In development
Primary therapeutic area(s): Oncology
Phase of development: Pre-clinical